Navigation Links
Apricoxib Prolongs Time-to-Progression and Overall Survival in Biomarker-Selected NSCLC Patients
Date:6/6/2011

II randomized trial of apricoxib in combination with erlotinib and gemcitabine for the first-line treatment of patients with pancreatic cancer.

About Capoxigem® (apricoxib, TG01)

Capoxigem (apricoxib, TG01) is an oral, once-daily selective COX-2 inhibitor. It is being evaluated for the treatment of cancer. Capoxigem affects a number of different oncogenic signaling pathways, including the HIF-1, VEGF, VEGF-R and PDGF systems for angiogenesis; the EGFR, HER2/neu, Bcr/Abl for growth control and differentiation; the intrinsic and extrinsic pathways for apoptosis; and the integrin and metalloproteinase systems for tissue invasion and metastasis. Capoxigem also potently inhibits COX-2-derived PGE2 production, reversing the PGE2-dependent epithelial-mesenchymal transition (EMT) process and the associated progression and metastasis of solid tumors. In pre-clinical cancer models, Capoxigem has shown superiority to compounds with similar mechanisms of action and synergy in combination with cisplatin, trastuzumab, and pemetrexed.

Capoxigem added to erlotinib therapy in a clinically relevant subset of biomarker-selected patients with advanced refractory non-small cell lung cancer significantly prolonged time to progression, progression-free survival and overall survival in a Phase II proof-of-concept study (APRiCOT-L). In clinical studies to date, Capoxigem has been well tolerated with a manageable side effect profile.

In addition to the APRiCOT-L study, a Phase II study of Capoxigem in pancreatic cancer recently completed enrollment and an investigator initiated study of Capoxigem in NSCLC in combination with chemotherapy is currently underway in the United States.

Apricoxib is also being evaluated for the treatment of inflammation-related pain. In inflammation-related pain, Capoxigem modulates the cyclooxygenase pathway, reducing the production of inflammatory prostaglandins. A large Phase IIa Proof-of-Concept and dose finding st
'/>"/>

SOURCE Tragara Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Tragara Pharmaceuticals Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis
2. Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
3. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
4. Treating Depression Prolongs Life for Older People with Diabetes
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Bayers Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
7. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
8. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
9. Dendreon Announces Exercise and Closing of Overallotment Option
10. Pharmasset Announces Exercise of Underwriters Overallotment Option
11. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Medical devices ... nor a biological product. In light of their different ... evaluations are much more complicated than drug trails due ... evaluates MD safety instead of evaluating both safety and ... US FDA (which is the same as the SFDA) ...
(Date:5/17/2013)... and CAMBRIDGE, Mass., May 17, 2013   Shareholder rights ... of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) securities has filed ... District of Massachusetts .  The complaint ... the Securities Exchange Act of 1934 (the "Exchange Act") ... "Class Period"). (Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO ) ...
(Date:5/17/2013)... 17, 2013  TechAtlas Group has announced the ... landscape map for the Chronic Kidney Disease (CKD) ... companies with drugs and devices currently on the ... sequelae. (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... hypertension - renal denervation , diabetic nephropathy ...
Breaking Medicine Technology:Statistical Challenges in Medical Device Trail Evaluation 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2
... , , HONG KONG, ... world,s first pro-healing stent, OrbusNeich,s Genous Bio-engineered R stent, and ... presented next week at the Transcatheter Cardiovascular Therapeutics symposium, TCT ... de Winter, M.D., Ph.D., of the Academic Medical Center in ...
... , SAN DIEGO, Sept. 14 Optimer ... presentation of results from its second prulifloxacin Phase 3 clinical ... clinical investigator Robert Steffen, M.D., at the annual Interscience Conference ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , ...
Cached Medicine Technology:Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009 3Data From Optimer's Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2Data From Optimer's Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 3Data From Optimer's Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 4Data From Optimer's Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 5
(Date:5/18/2013)... Dr. Robert Tracey, an area leader in dental laser ... of the root causes of sleep apnea to provide and ... Sleep Month, Dr. Tracey points out estimates revealing that 40 ... sleep apnea is one of the most common of all. ... breathing at different times while sleeping. When this happens, the ...
(Date:5/18/2013)... John Ravera, D.D.S., a Newport Beach cosmetic dentist ... to his dental team, Courtney Marino. , Marino is a ... 10 years. She received her degree from West Coast University, ... of Sigma Pi Alpha, a national honor society for individuals ... of all ages, helping them understand the importance of preventing ...
(Date:5/18/2013)... According to the the Stevens Johnson Syndrome Foundation, ... is a severe allergic reaction usually to medicine (i). ... can quickly advance causing blistering and large areas of dead ... SJS can develop at any time and seriously affect both ... Manute Bol, passed away after he received kidney medicine which ...
(Date:5/18/2013)... The product liability attorneys at Wright & Schulte ... consumers nationwide who have sustained serious tendon injuries allegedly caused ... are all part of MDL 2308 and were all filed ... be heard in the U.S. District Court of the Western ... LLC specializes in defending the rights of those who have ...
(Date:5/17/2013)... 2013 Daily Gossip announced on Monday that ... of the Program Yourself Thin regime, Jim Katsoulis. ... website by the end of the month in order to ... reeducate themselves and lead a healthy lifestyle, free of food ... package is available for only $97 and it comes ...
Breaking Medicine News(10 mins):Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 2Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 3Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2Health News:Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 3Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 4Health News:Program Yourself Thin Review and Secrets Revealed By Daily Gossip Magazine 2
... men are more at risk of diseases caused by blood ... of diseases caused by the inappropriate formation of a blood ... and stroke, but the reasons for this are not completely ... California, San Francisco, have used a mouse model of thrombosis ...
... review of 11 anti-seizure drugs that showed double the ... Anti-seizure drugs can cause increased suicidal tendencies in patients, ... 20-member panel of experts voted unanimously to back the ... Food and Drug Administration, the Associated Press ...
... are just a few of the extra costs that ... a new study that will be published in current ... social work at Washington University in St. Louis, found ... children,s special needs have different out-of-pocket health expenditures depending ...
... Today, PRINCETON, N.J., July 10 ... alerts and travel security,information from renowned intelligence ... http://www.securassist.com . The redesigned site, launched today, ... for preventing and,handling travel security emergencies., ...
... reported preliminary total retail drug,store sales for the 5-week, 9-week and 22-week periods ended July 3, 2008., , ... Periods ended July 3, 2008, ... Quarter Year ... to Date to Date (Dollars in millions) ...
... from UCLA and the Veterans Affairs Greater Los Angeles ... wearable artificial kidney, or AWAK, that avoids the complications ... , The design for the peritoneal-based artificial kidney ... loss and other dialysis-related problems is summarized in ...
Cached Medicine News:Health News:JCI online early table of contents: July 10, 2008 2Health News:JCI online early table of contents: July 10, 2008 3Health News:JCI online early table of contents: July 10, 2008 4Health News:JCI online early table of contents: July 10, 2008 5Health News:JCI online early table of contents: July 10, 2008 6Health News:JCI online early table of contents: July 10, 2008 7Health News:JCI online early table of contents: July 10, 2008 8Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 3Health News:Cost of raising a child with special needs: Where does your state rank? 2Health News:Assist America's New SecurAssist Website Features Top Travel Security Information Powered by iJET 2Health News:Longs Reports Preliminary June Retail Drug Store Sales 2Health News:Researchers design model for automated, wearable artificial kidney 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: